Acasti Pharma Inc. (ACST: Quote, APO.V) Tuesday reported third-quarter net loss of $1.6 million or $0.02 per share, compared to net loss of $2.2 million or $0.03 per share last year.
During the quarter, Acasti generated revenues of $424,000 from sales of Onemia, while it did not generate revenues from sales in the prior year.
Research and development expenses for the quarter totaled $770,000, compared to $1.4 million a year ago.
Click here to receive FREE breaking news email alerts for Acasti Pharma, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.comBusiness News